Clinical Trials

argenx has clinical trials ongoing across its differentiated antibody pipeline

Efgartigimod

Myasthenia Gravis (MG)

ADAPT

Phase 3 trial of IV efgartigimod for the treatment of generalized MG. Completed.
Program: Efgartigimod

Primary Immune Thrombocytopenia (ITP)

ADVANCE SC

Phase 3 trial evaluating SC efgartigimod for the treatment of primary ITP
Program: Efgartigimod

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Pemphigus Vulgaris (PV)

Bullous Pemphigoid

BALLAD

Phase 3 trial of SC efgartigimod for the treatment of BP (Bullous Pemphigoid)
Program: Efgartigimod

argenx BP Study website

ARGX-117

Multifocal Motor Neuropathy (MMN)

ARGX-117

ARGX-117 Phase 1 healthy volunteer trial
Program: ARGX-117